All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The Lupus Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lupus Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lupus Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lupus Hub cannot guarantee the accuracy of translated content. The Lupus Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lupus Hub is an independent medical education platform, supported through a grant from AstraZeneca. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Key communications on lupus at ACR 2022
Featured
Following the American College of Rheumatology annual meeting (ACR Convergence 2022), the Lupus Hub was pleased to speak to Murray Urowitz, University of Toronto, Toronto, CA. We asked, What were the key communications on lupus at ACR 2022?
Key communications on lupus at ACR 2022
In this podcast, Urowitz discusses five new therapies for lupus, as presented at ACR 2022, including deucravacitinib, litifilimab, zetomipzomib, telitacicept, and CAR T-cell agents. Urowitz outlines the mechanism of action for these therapies, highlighting the specific pathways targeted by different agents. Urowitz then provides data from clinical trials assessing these therapies and discusses their potential applications in lupus. Urowitz concludes by discussing two existing biologics, anifrolimab and voclosporin, and discussing 3-year follow up data in terms of the long-term efficacy and safety of these established treatments.
Related articles
Newsletter
Subscribe to get the best content related to lupus delivered to your inbox